The p21-activated kinase (PAK) family includes several enzyme isoforms regu
lated by the GTPases Rac1 and Cdc42, PAK1, found in brain, muscle and splee
n, has been implicated in triggering cytoskeletal rearrangements such as th
e dissolution of stress fibers and reorganization of focal complexes. The r
ole of the more widely distributed PAK2 in controlling the cytoskeleton has
been less well studied. Previous work has demonstrated that PAK2 can monop
hosphorylate the myosin II regulatory light chain and induce retraction of
permeabilized endothelial cells. In this report we characterize PAK2's morp
hological and biochemical effect on intact endothelial cells utilizing micr
oinjection of constitutively active PAK2 Under these conditions we observed
a modification of the actin cytoskeleton with retraction of endothelial ce
ll margins accompanied by an increase in monophosphorylation of myosin II.
Selective inhibitors were used to analyze the mechanism of action of PAK2,
Staurosporine, a direct inhibitor of PAK2, largely prevented the action of
microinjected PAK2 in endothelial cells. Butanedione monoxime, a non-specif
ic myosin ATPase inhibitor, also inhibited the effects of PAK2 implicating
myosin in the changes in cytoskeletal reorganization. In contrast, KT5926,
a specific inhibitor of myosin light chain kinase was ineffective in preven
ting the changes in morphology and the actin cytoskeleton, The additional f
inding that endogenous PAK2 associates with myosin II is consistent with th
e proposal that cell retraction and cytoskeletal rearrangements induced by
microinjected PAK2 depend on the direct activation of myosin II by PAK2 mon
ophosphorylation of the regulatory light chain.